These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 23195186)

  • 1. Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH).
    Bach D; Schmitt M; Ebeling L
    Phytomedicine; 1997 Feb; 3(4):309-13. PubMed ID: 23195186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors.
    Elterman DS; Lawrentschuk N; Guns E; Hersey K; Adomat H; Wood CA; Fleshner N
    J Urol; 2010 May; 183(5):2085-9. PubMed ID: 20303529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia.
    Feneley MR; Span PN; Schalken JA; Harper M; Griffiths K; Holmes K; Kirby RS
    Prostate Cancer Prostatic Dis; 1999 Dec; 2(5/6):277-281. PubMed ID: 12497174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5alpha-reductase inhibitors/finasteride.
    Stoner E
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is transurethral microwave thermotherapy an alternative to medical therapy for patients with benign prostatic hyperplasia?
    Djavan B
    Tech Urol; 2000 Dec; 6(4):300-6. PubMed ID: 11108570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [With alpha blockers, finasteride and nettle root against benign prostatic hyperplasia. Which patients are helped by conservative therapy?].
    Vahlensieck W
    MMW Fortschr Med; 2002 Apr; 144(16):33-6. PubMed ID: 12043098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finasteride in the treatment of patients with moderate symptoms of benign prostatic hyperplasia.
    Magoha GA
    East Afr Med J; 1998 May; 75(5):260-3. PubMed ID: 9746993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Status of phytotherapeutic drugs in treatment of benign prostatic hyperplasia].
    Dreikorn K; Schönhöfer PS
    Urologe A; 1995 Mar; 34(2):119-29. PubMed ID: 7538709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA
    Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benign prostatic hyperplasia. Hormonal treatment.
    McConnell JD
    Urol Clin North Am; 1995 May; 22(2):387-400. PubMed ID: 7539183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha adrenergic antagonists for the treatment of symptomatic BPH.
    Lepor H
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):151-5. PubMed ID: 2469658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
    Dolder CR
    Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current drug therapy of benign prostatic hyperplasia].
    Schmidbauer CP; Madersbacher S
    Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
    J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of 5-alpha-reductase inhibitors on the number of prostatectomies for benign prostatic hyperplasia.
    Agha AH; Roy JB; Culkin DJ; Lyon K
    Adv Ther; 1995; 12(6):361-6. PubMed ID: 10163332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.